Wall Street Zen Downgrades BioNTech (NASDAQ:BNTX) to Sell

BioNTech (NASDAQ:BNTX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

BNTX has been the subject of a number of other reports. Leerink Partners cut shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target for the company. in a research report on Monday, February 2nd. BMO Capital Markets cut their target price on BioNTech from $143.00 to $128.00 and set an “outperform” rating on the stock in a research report on Wednesday. The Goldman Sachs Group reissued a “buy” rating on shares of BioNTech in a report on Wednesday. Truist Financial set a $155.00 target price on BioNTech in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Friday, January 9th. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $133.73.

BioNTech Trading Up 1.2%

Shares of BioNTech stock opened at $91.19 on Friday. The company has a fifty day simple moving average of $106.43 and a 200-day simple moving average of $102.56. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a current ratio of 7.54, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. The stock has a market cap of $20.53 billion, a price-to-earnings ratio of -17.40 and a beta of 1.51.

Institutional Trading of BioNTech

Several hedge funds have recently made changes to their positions in BNTX. Royal Bank of Canada increased its stake in BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after purchasing an additional 3,514 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in BioNTech in the first quarter valued at $167,000. Envestnet Asset Management Inc. increased its position in shares of BioNTech by 20.6% in the second quarter. Envestnet Asset Management Inc. now owns 10,570 shares of the company’s stock valued at $1,125,000 after buying an additional 1,808 shares in the last quarter. Allworth Financial LP increased its position in shares of BioNTech by 1,176.8% in the second quarter. Allworth Financial LP now owns 1,213 shares of the company’s stock valued at $129,000 after buying an additional 1,118 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its position in shares of BioNTech by 5.2% in the 2nd quarter. SBI Securities Co. Ltd. now owns 3,865 shares of the company’s stock worth $412,000 after buying an additional 192 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.